Thomas Passie
Psychiatrist and Psychopharmacologist
Data updated
Research Footprint
Thomas Passie appears in 13 tracked papers (2002–2023), most studied alongside MDMA, LSD and Ketamine, across Substance Use Disorders (SUD), Healthy Volunteers and Anxiety Disorders.
Most-cited paper: Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases (744 citations).
Frequent co-authors: James Halpern, Simon Brandt and Yasmin Schmid.
Background & Research
Thomas Passie is a clinician-researcher whose work spans clinical trials, human pharmacology, and historical/pharmacological scholarship in the field of psychedelic substances. His publications and trials include human volunteer research comparing entactogens (e.g. MDAI versus MDMA), investigations of LSD-assisted psychotherapy for anxiety associated with life‑threatening illness, epidemiological and safety studies of sacramental hallucinogen use, and accounts of the rediscovery and pharmacology of MDMA. He has also reported clinical case series exploring the use of the non‑hallucinogenic analogue 2‑bromo‑LSD as a preventative treatment for cluster headache.
Key Impact
Noted for clinical and pharmacological research on LSD, MDMA and related compounds, and for translational work on psychedelic-assisted therapies including investigation of non‑hallucinogenic ergoline analogues.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Thomas Passie is associated with.